9月2日 - ** 制药商Ionis Pharmaceuticals IONS.O 股价盘前上涨17%至50美元
** 该公司称其药物olezarsen在两项后期研究中使严重高甘油三酯血症患者的甘油三酯水平降低了72% (link)
** 该药还可将急性胰腺炎事件减少 85
** 高甘油三酯血症是一种血液中脂肪含量过高的疾病，会增加罹患心脏病和胰腺炎的风险。
** 甘油三酯是血液中的一种脂肪，人体用它来获取能量
** 公司计划在年底前提交补充上市申请
** Olezarsen去年获得FDA批准，用于治疗家族性乳糜微粒血症综合征（Familial chylomicronemia syndrome (link)），这种疾病会阻碍人体分解脂肪，其特征是甘油三酯水平极高。
** 截至上一交易日收盘，股价累计上涨 22
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.